Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.
Mantovani S, Daga S, Fallerini C, Baldassarri M, Benetti E, Picchiotti N, Fava F, Gallì A, Zibellini S, Bruttini M, Palmieri M, Croci S, Amitrano S, Alaverdian D, Capitani K, Furini S, Mari F, Meloni I; GEN-COVID Multicenter Study; Frullanti E, Mondelli MU, Renieri A. Mantovani S, et al. Among authors: alaverdian d. Genes Immun. 2022 Feb;23(1):51-56. doi: 10.1038/s41435-021-00157-1. Epub 2021 Dec 24. Genes Immun. 2022. PMID: 34952932 Free PMC article.
Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide.
Chernov AN, Alaverdian DA, Glotov OS, Talabaev MV, Urazov SP, Shcherbak SG, Renieri A, Frullanti E, Shamova O. Chernov AN, et al. Drug Metab Pers Ther. 2020 Sep 16:/j/dmdi.ahead-of-print/dmdi-2020-0109/dmdi-2020-0109.xml. doi: 10.1515/dmdi-2020-0109. Online ahead of print. Drug Metab Pers Ther. 2020. PMID: 32887179
Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants.
Baldassarri M, Fava F, Fallerini C, Daga S, Benetti E, Zguro K, Amitrano S, Valentino F, Doddato G, Giliberti A, Di Sarno L, Palmieri M, Carriero ML, Alaverdian D, Beligni G, Iuso N, Castelli F, Quiros-Roldan E, Mondelli MU, Miceli R, Frullanti E, Furini S, Mari F, Renieri A, Gabbi C, On Behalf Of The Gen-Covid Multicenter Study. Baldassarri M, et al. Among authors: alaverdian d. J Pers Med. 2021 Jun 15;11(6):558. doi: 10.3390/jpm11060558. J Pers Med. 2021. PMID: 34203982 Free PMC article.
C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age.
Zanella I, Zacchi E, Piva S, Filosto M, Beligni G, Alaverdian D, Amitrano S, Fava F, Baldassarri M, Frullanti E, Meloni I, Renieri A; GEN-COVID Multicenter Study; GEVACOBA Study Group; Castelli F, Quiros-Roldan E. Zanella I, et al. Among authors: alaverdian d. Int J Mol Sci. 2021 Jun 29;22(13):6991. doi: 10.3390/ijms22136991. Int J Mol Sci. 2021. PMID: 34209673 Free PMC article.
The Phenomenon of Multidrug Resistance in Glioblastomas.
Chernov AN, Alaverdian DA, Galimova ES, Renieri A, Frullanti E, Meloni I, Shamova OV. Chernov AN, et al. Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):1-7. doi: 10.1016/j.hemonc.2021.05.006. Hematol Oncol Stem Cell Ther. 2022. PMID: 34216549 Review.
Mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative. COVID-19 Host Genetics Initiative. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8. Nature. 2021. PMID: 34237774 Free PMC article.
SELP Asp603Asn and severe thrombosis in COVID-19 males.
Fallerini C, Daga S, Benetti E, Picchiotti N, Zguro K, Catapano F, Baroni V, Lanini S, Bucalossi A, Marotta G, Colombo F, Baldassarri M, Fava F, Beligni G, Di Sarno L, Alaverdian D, Palmieri M, Croci S, Isidori AM, Furini S, Frullanti E; GEN-COVID Multicenter Study; Renieri A, Mari F. Fallerini C, et al. Among authors: alaverdian d. J Hematol Oncol. 2021 Aug 16;14(1):123. doi: 10.1186/s13045-021-01136-9. J Hematol Oncol. 2021. PMID: 34399825 Free PMC article.
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, Ellinghaus D, Khan A, Martínez-Bueno M, Rolker S, Amitrano S, Roade Tato L, Fava F; FinnGen; COVID-19 Host Genetics Initiative (HGI); Spinner CD, Prati D, Bernardo D, Garcia F, Darcis G, Fernández-Cadenas I, Holter JC, Banales JM, Frithiof R, Kiryluk K, Duga S, Asselta R, Pereira AC, Romero-Gómez M, Nafría-Jiménez B, Hov JR, Migeotte I, Renieri A, Planas AM, Ludwig KU, Buti M, Rahmouni S, Alarcón-Riquelme ME, Schulte EC, Franke A, Karlsen TH, Valenti L, Zeberg H, Richards JB, Ganna A. Nakanishi T, et al. J Clin Invest. 2021 Dec 1;131(23):e152386. doi: 10.1172/JCI152386. J Clin Invest. 2021. PMID: 34597274 Free PMC article. Clinical Trial.
Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide.
Chernov AN, Alaverdian DA, Glotov OS, Talabaev MV, Urazov SP, Shcherbak SG, Renieri A, Frullanti E, Shamova O. Chernov AN, et al. Drug Metab Pers Ther. 2020 Sep 4;35(4). doi: 10.1515/dmpt-2020-0109. Drug Metab Pers Ther. 2020. PMID: 34704697
22 results